Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs SkyWest Inc (SKYW) Price & Performance

AbbVie IncTrade
SkyWest IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs SkyWest Inc — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while SkyWest Inc trades at $107.91 (market cap $4.18B). The key difference: AbbVie Inc is far larger — about 104.8× SkyWest Inc's market cap, and AbbVie Inc pays a 2.79% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.

ABBVSKYW
Market Cap
$438.19B$4.18B
Sector
HealthTechnology
52-Week High
$263.58$123.72
52-Week Low
$197.38$78.40
Enterprise Value
$502.45B$5.96B
Dividend Yield
2.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

SkyWest Inc

SkyWest (SKYW) trades at $111.84, down 1.41% on the day, with a bullish technical signal supported by moving averages and a consensus analyst buy rating. Recent Q2 2026 earnings missed estimates at $2.54 EPS versus $2.70 expected, but revenue trends show growth to $4.2B in 2026. The stock benefits from strong profitability with a 9.78% net margin and attractive valuation metrics, including a P/E of 10.69. Key developments include executive stock sales and a 7.7% post-earnings rally noted by Zacks on July 27, 2026.

Outlook remains positive due to undervaluation and fleet expansion, but risks include fuel cost volatility from Iran war impacts (New York Post, July 7, 2026) and insider selling. The consensus price target of $109.33 suggests limited upside, with execution on earnings beats being critical for further gains.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About SkyWest Inc

SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.

Read more on SKYW